DPP4 inhibitors have been proposed to lower blood glucose primarily through inhibiting the degradation of GLP-1 and are recommended as a first-line hypoglycemic treatment in T2DM by the American Association of Clinical Endocrinologists (Drucker and Nauck, 2006; Handelsman et al., 2015). Here, GLP1R is linked to type 2 diabetes mellitus.